Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
16.99
+1.44 (9.26%)
Bozor ochiq: Aug 12, 2026, 11:53 AM EDT
15.45
-0.10 (-0.64%)
Oldingi bozordan keyin: Aug 11, 2026, 7:35 PM EDT
Greenwich LifeSciences, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda ko'krak bezi saratoni va HER2/neu ekspressiya qiluvchi boshqa saraton turlari uchun yangi rak immunoterapiyalarini ishlab chiqadi. Uning yetakchi mahsulot nomzodi GP2, HER2/neu transmembran peptidi, bemorlarda ko'krak bezi saratoni takrorlanishini oldini olish uchun III bosqich klinik sinovda. Kompaniya, shuningdek, FLAMINGO-01 ni ishlab chiqmoqda, bu HER2 musbat ko'krak bezi saratoni bemorlarida GLSI-100 ning xavfsizligi va samaradorligini baholash uchun mo'ljallangan IIb bosqich va 3 ta I bosqich klinik sinovda. Greenwich LifeSciences, Inc. ilgari Norwell, Inc. nomi bilan tanilgan va 2018 yil mart oyida Greenwich LifeSciences, Inc. nomini o'zgartirgan. Kompaniya 2006 yilda tashkil etilgan va shtab-kvartirasi Stafford, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christine T. Fischette Ph.D. | VP of Business Development |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs |
| Mr. Eric Rothe | Founder & Independent Director |
| Mr. Snehal S. Patel | CEO, CFO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-11 | 10-Q | form10-q.htm |
| 2026-06-04 | 10-Q | form10-q.htm |
| 2026-06-01 | 10-K | form10-k.htm |
| 2026-03-31 | NT 10-K | formnt10-k.htm |
| 2025-12-18 | 8-K | form8-k.htm |
| 2025-11-14 | 10-Q | form10-q.htm |
| 2025-11-03 | DEFA14A | formdefa14a.htm |
| 2025-11-03 | DEF 14A | formdef14a.htm |
| 2025-11-03 | ARS | formars.pdf |
| 2025-08-14 | 10-Q | form10-q.htm |